The investigation centers on whether Cellectis and its leadership misrepresented the firm's financial health or business practices prior to the September 14 announcement. During a conference call that day, Chief Medical Officer Adrian Kilcoyne admitted the company lacked the necessary cash resources to continue developing the lasme-cel and eti-cel therapies. Instead, Cellectis signaled a strategic pivot toward in vivo gene editing projects, specifically HEAL-101 and HEAL-201.
Pomerantz LLP Launches Investigation Into Cellectis Securities Practices
A 41 percent plunge in Cellectis S.A. stock has triggered a formal investigation by Pomerantz LLP into potential securities fraud. The inquiry follows the company's abrupt decision to abandon key CAR-T cell therapy programs, a move executives attributed to severe capital constraints and unfavorable development timelines.
Following the disclosure, the company's American Depositary Receipt price dropped $1.27, closing at $1.83. Investors who suffered losses are now being urged to contact Pomerantz LLP to discuss potential participation in a class action suit. The firm, known for its focus on corporate misconduct and fiduciary breaches, is currently evaluating whether shareholders were misled about the viability of the discontinued programs.
Comments (0)
No comments yet. Be the first!